Abstract
Paclitaxel and carboplatin is widely used in the treatment of patients with advanced non-small cell lung cancer (NSCLC); however, median survival remains <1 year. One strategy to improve survival is to add a third active drug with a differing mechanism of action. Gemcitabine is a novel antimetabolite with considerable activity in NSCLC. The primary objective of this Phase I/II study was to determine the maximally tolerated dose of gemcitabine administered with fixed doses of paclitaxel and carboplatin in untreated patients with advanced NSCLC.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 3474-3479 |
| Number of pages | 6 |
| Journal | Clinical Cancer Research |
| Volume | 6 |
| Issue number | 9 |
| State | Published - 2000 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
A Phase I/II trial of paclitaxel, carboplatin, and gemcitabine in untreated patients with advanced non-small cell lung cancer. / Kelly, Karen; Mikhaeel-Kamel, N.; Pan, Z.; Murphy, J.; Prindiville, S.; Bunn P.A., Jr.
In: Clinical Cancer Research, Vol. 6, No. 9, 2000, p. 3474-3479.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A Phase I/II trial of paclitaxel, carboplatin, and gemcitabine in untreated patients with advanced non-small cell lung cancer
AU - Kelly, Karen
AU - Mikhaeel-Kamel, N.
AU - Pan, Z.
AU - Murphy, J.
AU - Prindiville, S.
AU - Bunn P.A., Jr
PY - 2000
Y1 - 2000
N2 - Paclitaxel and carboplatin is widely used in the treatment of patients with advanced non-small cell lung cancer (NSCLC); however, median survival remains <1 year. One strategy to improve survival is to add a third active drug with a differing mechanism of action. Gemcitabine is a novel antimetabolite with considerable activity in NSCLC. The primary objective of this Phase I/II study was to determine the maximally tolerated dose of gemcitabine administered with fixed doses of paclitaxel and carboplatin in untreated patients with advanced NSCLC.
AB - Paclitaxel and carboplatin is widely used in the treatment of patients with advanced non-small cell lung cancer (NSCLC); however, median survival remains <1 year. One strategy to improve survival is to add a third active drug with a differing mechanism of action. Gemcitabine is a novel antimetabolite with considerable activity in NSCLC. The primary objective of this Phase I/II study was to determine the maximally tolerated dose of gemcitabine administered with fixed doses of paclitaxel and carboplatin in untreated patients with advanced NSCLC.
UR - http://www.scopus.com/inward/record.url?scp=0033817994&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033817994&partnerID=8YFLogxK
M3 - Article
C2 - 10999731
AN - SCOPUS:0033817994
VL - 6
SP - 3474
EP - 3479
JO - Clinical Cancer Research
JF - Clinical Cancer Research
SN - 1078-0432
IS - 9
ER -